{"id":"nucs","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"NUCS works by binding to the SARS-CoV-2 main protease, thereby inhibiting the viral replication. This mechanism of action is crucial in the treatment of COVID-19. The exact binding affinity and specificity of NUCS to the SARS-CoV-2 main protease are still being studied.","oneSentence":"NUCS is a small molecule that targets the SARS-CoV-2 main protease.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:23:38.144Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of COVID-19"}]},"trialDetails":[{"nctId":"NCT07135349","phase":"PHASE2","title":"A Phase II Clinical Study of BW-20507 in Combination With PEG-IFNα for the Treatment of Hepatitis B","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Argo Biopharmaceutical Co., Ltd.","startDate":"2025-09-02","conditions":"Chronic Hepatitis B","enrollment":209},{"nctId":"NCT02797522","phase":"PHASE1","title":"A Study of ARC-521 Injection in Normal Adult Volunteers and Patients With Chronic Hepatitis B (CHB)","status":"TERMINATED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2016-06","conditions":"Hepatitis B","enrollment":47},{"nctId":"NCT07179575","phase":"PHASE1, PHASE2","title":"Study of LW231 in Participants With Chronic Hepatitis B","status":"RECRUITING","sponsor":"Shanghai Longwood Biopharmaceuticals Co., Ltd.","startDate":"2025-10","conditions":"Chronic HBV Infection","enrollment":270},{"nctId":"NCT05960240","phase":"PHASE1","title":"Safety, Tolerability, PK & PD of AB-101 Following Oral Administration in Healthy and CHB Subjects.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Arbutus Biopharma Corporation","startDate":"2023-08-30","conditions":"Chronic Hepatitis b","enrollment":128},{"nctId":"NCT04102176","phase":"NA","title":"Halting Nucleoside Analogues in Chronic Hepatitis B","status":"ACTIVE_NOT_RECRUITING","sponsor":"Seng Gee Lim","startDate":"2019-01-29","conditions":"Chronic Hepatitis B","enrollment":120},{"nctId":"NCT04846491","phase":"PHASE3","title":"A Study of Peginterferon Alfa-2b Combined With TDF in Patients With Chronic Hepatitis B","status":"COMPLETED","sponsor":"Xiamen Amoytop Biotech Co., Ltd.","startDate":"2019-12-04","conditions":"Chronic Hepatitis B","enrollment":475},{"nctId":"NCT03736265","phase":"NA","title":"Carvedilol for Prevention of Esophageal Varices Progression","status":"UNKNOWN","sponsor":"Beijing Friendship Hospital","startDate":"2017-10-09","conditions":"Cirrhosis, Liver, Portal Hypertension","enrollment":240},{"nctId":"NCT03434353","phase":"PHASE2","title":"Study to Evaluate the Safety and Antiviral Activity of Inarigivir Soproxil (Formerly: GS-9992) Plus Tenofovir Alafenamide (TAF) for 12 Weeks in Adults With Chronic Hepatitis B (CHB)","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2018-02-28","conditions":"Chronic Hepatitis B","enrollment":123},{"nctId":"NCT05086536","phase":"","title":"Re-compensation and Its Clinical Characteristics in HBV Decompensated Cirrhosis","status":"UNKNOWN","sponsor":"Beijing Friendship Hospital","startDate":"2021-10-15","conditions":"Hepatitis B, Decompensated Cirrhosis","enrollment":600},{"nctId":"NCT05021406","phase":"NA","title":"Extension Study of Carvedilol RCT Study","status":"UNKNOWN","sponsor":"Beijing Friendship Hospital","startDate":"2021-01-08","conditions":"Liver Cirrhosis, Portal Hypertension","enrollment":240},{"nctId":"NCT04290936","phase":"PHASE4","title":"Tenofovir Alafenamide(TAF) Reduces the Risk of Hepatocellular Carcinoma(HCC) Recurrence","status":"UNKNOWN","sponsor":"Taipei Veterans General Hospital, Taiwan","startDate":"2020-10-16","conditions":"HCC Patients After Curative Treatment With Low HBV Viral Load","enrollment":402},{"nctId":"NCT00379405","phase":"PHASE4","title":"Saquinavir/Ritonavir in Single Therapy as Maintenance Treatment","status":"COMPLETED","sponsor":"Germans Trias i Pujol Hospital","startDate":"2006-06","conditions":"HIV Infections","enrollment":30},{"nctId":"NCT03798119","phase":"PHASE4","title":"TAF Switch in F3/4 CHB pt With Partial Response to NUC (ESTAB-AFPVR)","status":"UNKNOWN","sponsor":"Kaohsiung Medical University Chung-Ho Memorial Hospital","startDate":"2019-02-25","conditions":"Hepatitis B, Fibrosis and Cirrhosis of Liver","enrollment":80},{"nctId":"NCT02249988","phase":"PHASE2, PHASE3","title":"Clinical Efficacy of ABX203 Therapeutic Vaccine in HBeAg Negative Patients With Chronic Hepatitis B","status":"COMPLETED","sponsor":"Abivax S.A.","startDate":"2014-12","conditions":"Chronic Hepatitis B","enrollment":261},{"nctId":"NCT00437684","phase":"PHASE3","title":"Lopinavir/Ritonavir Monotherapy Versus Standard Highly Active Antiretroviral Therapy (HAART) in HIV/HCV Coinfected Patients Starting Treatment With Anti-Hepatitis C Virus (HCV) Therapy","status":"UNKNOWN","sponsor":"IRCCS San Raffaele","startDate":"2007-02","conditions":"HIV Infections, Hepatitis C","enrollment":50},{"nctId":"NCT00437476","phase":"PHASE3","title":"Lopinavir/Ritonavir Monotherapy Versus Standard Highly Active Antiretroviral Therapy (HAART) in HIV/HCV Coinfected Antiretroviral (ARV) Naive Patients Starting Treatment With Anti-HCV Therapy","status":"UNKNOWN","sponsor":"IRCCS San Raffaele","startDate":"2007-02","conditions":"HIV Infections, Hepatitis C","enrollment":60},{"nctId":"NCT00314626","phase":"PHASE3","title":"Antiretroviral Treatment Simplification Study With Efavirenz + Abacavir + 3TC Once Daily","status":"COMPLETED","sponsor":"Germans Trias i Pujol Hospital","startDate":"2004-11","conditions":"HIV Infections","enrollment":99}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":330,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"NUCS","genericName":"NUCS","companyName":"IRCCS San Raffaele","companyId":"irccs-san-raffaele","modality":"Small molecule","firstApprovalDate":"","aiSummary":"NUCS is a small molecule that targets the SARS-CoV-2 main protease. Used for Treatment of COVID-19.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}